Literature DB >> 35261792

Systematic review of the predictors of health service use in pancreatic cancer.

Nadia N Khan1, Tennille Lewin1, Amy Hatton1, Charles Pilgrim1, Liane Ioannou1, Luc Te Marvelde1, John Zalcberg1, Sue Evans1.   

Abstract

INTRODUCTION: Pancreatic cancer (PC) has a dismal prognosis, with identified disparities in survival outcomes based on demographic characteristics. These disparities may be ameliorated by equitable access to treatments and health services. This systematic review identifies patient and service-level characteristics associated with PC health service utilisation (HSU).
METHODS: Medline, Embase, CINAHL, PsycINFO and Scopus were systematically searched between 1st January, 2010 and 17 May, 2021 for population-based, PC studies which conducted univariable and/or multivariable regression analyses to identify patient and/or service-level characteristics associated with use of a treatment or health service. Direction of effect sizes were reported in an aggregate manner.
RESULTS: Sixty-two eligible studies were identified. Most (48/62) explored the predictors of surgery (n=25) and chemotherapy (n=23), and in populations predominantly based in the United States of America (n=50). Decreased HSU was observed among people belonging to older age groups, non-Caucasian ethnicities, lower socioeconomic status (SES) and lower education status. Non-metropolitan location of residence predicted decreased use of certain treatments, and was associated with reduced hospitalisations. People with comorbidities were less likely to use treatments and services, including specialist consultations and palliative care but were more likely to be hospitalised. A more recent year of diagnosis/year of death was generally associated with increased HSU. Academically affiliated and high-volume centres predicted increased treatment use and hospital readmissions.
CONCLUSION: Findings of this review may assist identification of vulnerable patient groups experiencing disparities in accessing and using treatments and therapies. AJCR
Copyright © 2022.

Entities:  

Keywords:  Pancreatic neoplasms; health services; resource allocation

Year:  2022        PMID: 35261792      PMCID: PMC8900007     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  81 in total

1.  Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience.

Authors:  C Max Schmidt; Olivier Turrini; Purvi Parikh; Michael G House; Nicholas J Zyromski; Atilla Nakeeb; Thomas J Howard; Henry A Pitt; Keith D Lillemoe
Journal:  Arch Surg       Date:  2010-07

2.  Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.

Authors:  Linda M Youngwirth; Daniel P Nussbaum; Samantha Thomas; Mohamed A Adam; Dan G Blazer; Sanziana A Roman; Julie A Sosa
Journal:  J Surg Oncol       Date:  2017-04-13       Impact factor: 3.454

3.  Refusing treatment.

Authors:  Moshe Frenkel
Journal:  Oncologist       Date:  2013

4.  Healthcare disparities in outcomes of patients with resectable pancreatic cancer.

Authors:  Omeed Moaven; Joshua S Richman; Sushanth Reddy; Thomas Wang; Martin J Heslin; Carlo M Contreras
Journal:  Am J Surg       Date:  2018-12-10       Impact factor: 2.565

5.  Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices.

Authors:  Jessica P Simons; Sing Chau Ng; Theodore P McDade; Zheng Zhou; Craig C Earle; Jennifer F Tseng
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

6.  Laparoscopic pancreatectomy for cancer in high volume centers is associated with an increased use and fewer delays of adjuvant chemotherapy.

Authors:  Onur C Kutlu; Eduardo A Vega; Omid Salehi; Christopher Lathan; Sunhee Kim; Sandeep Krishnan; Christopher Stallwood; Olga Kozyreva; Claudius Conrad
Journal:  HPB (Oxford)       Date:  2020-09-25       Impact factor: 3.647

7.  Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer.

Authors:  Lydia G M van der Geest; Nadia Haj Mohammad; Marc G H Besselink; Valery E P P Lemmens; Johanneke E A Portielje; Hanneke W M van Laarhoven; J Hanneke W Wilmink
Journal:  Cancer Med       Date:  2017-10-16       Impact factor: 4.452

8.  Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma.

Authors:  Emily Boevers; Bradley D McDowell; Sarah L Mott; Anna M Button; Charles F Lynch
Journal:  J Cancer Epidemiol       Date:  2017-04-10

Review 9.  A systematic review of the predictors of health service utilisation by adults with mental disorders in the UK.

Authors:  Conal D Twomey; David S Baldwin; Maren Hopfe; Alarcos Cieza
Journal:  BMJ Open       Date:  2015-07-06       Impact factor: 2.692

10.  The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis.

Authors:  Maikel J Bakens; Lydia G van der Geest; Magreet van Putten; Hanneke W van Laarhoven; Geert-Jan Creemers; Marc G Besselink; Valery E Lemmens; Ignace H de Hingh
Journal:  Cancer Med       Date:  2016-09-27       Impact factor: 4.452

View more
  1 in total

1.  Use of scheduled and unscheduled health services by cancer survivors and their caregivers.

Authors:  Alla Sikorskii; Chris Segrin; Tracy E Crane; Pavani Chalasani; Waqas Arslan; Jessica Rainbow; Mary Hadeed; Charles Given; Terry A Badger
Journal:  Support Care Cancer       Date:  2022-05-24       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.